



20th October 2008

**NORGINE NOTES "LOSS OF EXCLUSIVITY"
PROPOSALS DELAYED FOR LEGAL REVIEW**

Following on from today's news that the implementation of the so-called "Loss of Exclusivity" provisions of the proposed new PPRS scheme has been delayed, Norgine's Chief Operating Officer, Peter Martin, commented:

"Norgine is pleased that these ill-conceived proposals have been delayed for proper consultation.

I believe they create a policy which is contrary to the interests of the majority of the ABPI's members.

It has always been clear to us that the main intent of these proposed provisions was to protect the Big Pharma manufacturers of me-too blockbusters from the full effects of value based pricing, and that one consequence of this tactic was to sacrifice the interests of small and medium sized pharmaceuticals working hard to bring innovative medicines to the British patient.

I hope that this pause will allow the ABPI to consider its position and withdraw this unilateral scheme from consideration by the Department of Health, which has signalled that this is not a policy it has pursued or indeed that the Department welcomes. Norgine hopes that the proposed consultation will be expanded to encompass not just the products which are affected by these arrangements but also the wider implications of this policy upon the future of innovation in the pharmaceutical sector."

ENDS

If you would like any further information, or to set up an interview please contact:

Medicom Group: Olivia Spiro on 020 8481 8129 (olivias@medicomgroup.com) or Sarah Dyson on 07960195556 (sdyson@medicomgroup.com).

Notes to editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all the major European markets. In 2007 Norgine's sales were €220 million, the 21st consecutive year of double-digit growth. The company employs over 1,000 people of whom around 400 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. MOVICOL[®] for the treatment of chronic constipation and faecal impaction, MOVIPREP[®] a new generation bowel cleansing preparation, KLEAN-PREP[®] for bowel preparation prior to colonoscopy, and ORAMORPH[®] for the treatment of moderate to severe pain associated with cancer.

Norgine has an active Research and Development effort and currently has products at various stages of clinical development. In addition to its site at Hengoed, Norgine also has a manufacturing site at Dreux in France.

Norgine's website is www.norgine.com